Physician profile
Viktor Gribenko
NPI 1659471944
$6,034.63
in general payments reported to CMS, 2019-2025
20 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 91% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $418 · 2021: $538 · 2022: $787 · 2023: $1,095 · 2024: $702 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,181.95 | 2021-2025 | |
| Glaxosmithkline, LLC. | $609.42 | 2022-2024 | Shingrix, Arexvy |
| Pfizer INC. | $582.80 | 2019-2025 | |
| Indivior INC. | $491.49 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.26 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $250.96 | 2019-2020 | |
| Orexo US, INC. | $195.59 | 2019-2022 | |
| Astellas Pharma US INC | $140.00 | 2025 | Veozah |
| Tandem Diabetes Care, INC. | $138.17 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $132.62 | 2022 | |
| Medtronic, INC. | $127.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $124.93 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $120.66 | 2025 | Breztri |
| Novo Nordisk INC | $117.82 | 2021-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.09 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $62.95 | 2021-2022 | |
| Braeburn INC. | $61.36 | 2025 | Brixadi |
| Pear Therapeutics (US), INC. | $40.50 | 2021 | |
| Corium, LLC | $31.00 | 2023 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $20.83 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktor Gribenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.